Outcomes for Infants Born in Perinatal Centers Performing Fewer Surgical Ligations for Patent Ductus Arteriosus: A Swiss Population-Based Study by Adams, Mark et al.








Outcomes for Infants Born in Perinatal Centers Performing Fewer Surgical
Ligations for Patent Ductus Arteriosus: A Swiss Population-Based Study
Adams, Mark ; Schulzke, Sven M ; Natalucci, Giancarlo ; Schneider, Juliane ; Riedel, Thomas ; Tolsa,
Cristina Borradori ; Pfister, Riccardo ; Bassler, Dirk ; Meyer, Philipp ; Kusche, Rachel ; Mori, Andrea
Capone ; Kaeppeli, Daniela ; Schulzke, Sven M ; Brotzmann, Marc ; Ramelli, Gian Paolo ; Goeggel,
Barbara Simonetti ; McDougall, Jane ; Humpl, Tilman ; Steinlin, Maja ; Grunt, Sebastian ; Gebauer,
Mathias ; Hassink, Ralph ; Riedel, Thomas ; Keller, Elmar ; Killer, Christa ; Blanchard, Gaelle ;
Pfister, Riccardo E ; Huppi, Petra S ; Borradori-Tolsa, Cristina ; Tolsa, Jean-François ; Roth-Kleiner,
Matthias ; Bickle-Graz, Myriam ; Stocker, Martin ; Schmitt-Mechelke, Thomas ; Bauder, Florian ;
Erkert, Bernd ; Mueller, Anita ; Ecoffey, Marc ; Malzacher, Andreas ; Rogdo, Bjarte ; Lang-Dullenkopf,
Anette ; Hegi, Lukas ; von Rhein, Michael ; Bernet, Vera ; Tomaske, Maren ; Bassler, Dirk ; Arlettaz,
Romaine ; Hagmann, Cornelia ; Latal, Bea ; Etter, Ruth
Abstract: Objective To assess patent ductus arteriosus treatment variation between Swiss perinatal cen-
ters and to determine its effect on outcome in a population-based setting. Study design This was a
retrospective cohort study of infants born less than 28 weeks of gestation between 2012 and 2017. Out-
comes between surgically ligated and pharmacologically treated infants as well as infants born in centers
performing ฀10% ligation (“low” group) and >10% (“high” group) were compared using logistic regres-
sion and 1:1 propensity score matching. Matching was based on case-mix and preligation confounders:
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agreed-on common procedure. These results may guide a revision of patent ductus arteriosus treatment
practice in Switzerland.
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Outcomes for Infants Born in Perinatal Centers Performing Fewer Surgical
Ligations for Patent Ductus Arteriosus: A Swiss Population-Based Study
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Thomas Riedel, MD6, Cristina Borradori Tolsa, MD7, Riccardo Pfister, Prof, MD7, and Dirk Bassler, Prof, MD, MSc1,
for the Swiss Neonatal Network & Follow-Up Group*
Objective To assess patent ductus arteriosus treatment variation between Swiss perinatal centers and to deter-
mine its effect on outcome in a population-based setting.
Study design This was a retrospective cohort study of infants born less than 28 weeks of gestation between 2012
and 2017. Outcomes between surgically ligated and pharmacologically treated infants as well as infants born in
centers performing £10% ligation (“low” group) and >10% (“high” group) were compared using logistic regression
and 1:1 propensity score matching. Matching was based on case-mix and preligation confounders: intraventricular
hemorrhages grades 3-4, necrotizing enterocolitis, sepsis, and ³28 days’ oxygen supply.
Results Of 1389 infants, 722 (52%) had pharmacologic treatment and 156 (11.2%) received surgical ligation.
Compared with infants who received pharmacologic treatment, ligated infants had greater odds for major morbid-
ities (OR 2.09, 95%CI 1.44-3.04) and 2-year neurodevelopmental impairment (OR 1.81, 95% CI 1.15-2.84). Mortal-
ity was comparable after restricting the cohort to infants surviving at least until day 10 to avoid survival bias. In the
“low” group, 34 (4.9%) of 696 infants were ligated compared with 122 (17.6%) of 693 infants in the “high” group.
Infants in the “high” group had greater odds for major morbidities (OR 1.49, 95% CI 1.11-2.0).
Conclusions Our analysis identified a burden on infants receiving surgical ligation vs pharmacologic treatment in
a population-based setting where there was no agreed-on common procedure. These results may guide a revision
of patent ductus arteriosus treatment practice in Switzerland. (J Pediatr 2021;-:1-8).
P
atent ductus arteriosus (PDA) is a delay in the physiologic closure of the ductus arteriosus that connects the pulmonary
artery with the descending aorta. The time it takes to achieve spontaneous closure is inversely proportional to gesta-
tional age at birth, with some vessels requiring months to years to close.1 This delay has been associated with renal
dysfunction, intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), chronic lung disease, or retinopathy of pre-
maturity (ROP).1-3 There is no universally accepted definition or diagnosis; some definitions are based on clinical signs, some
require echocardiography, and some require pharmacologic treatment.4-7 Some clinicians perform diagnosis using routine
echocardiography, others require clinical signs, whereas the former will report greater incidences than the latter. Where re-
ported, prevalence is between 20% and 60% among infants born at less than 32 weeks of gestation.1,2,8 A study of 6 high-
income countries (including Switzerland) reported PDA treatment rates ranging from 38% to 52% in infants born less than
28 weeks of gestation and with a birth weight <1500 g.4 Classical treatment con-
sists of pharmacologic treatment with cyclo-oxygenase inhibitors (usually indo-
methacin or ibuprofen) or surgical ligation if the medication should fail or be
contraindicated. However, this approach has been challenged, and it therefore re-
mains unclear whether and when a pharmacologic or surgical approach is advan-
tageous.1,9,10
The uncertainty in clinical diagnosis and management of PDA has led to wide-
spread treatment variation among healthcare providers.4,7,11,12 The aim of our
study was to analyze the variation among Swiss perinatal centers, to assess the
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association of surgical ligation with short-term outcome after
primary hospitalization and long-term neurodevelopmental
outcome at 2 years, and to ascertain whether performing
fewer surgical ligations is associated with outcome. Previous
attempts report a lower mortality for ligation vs pharmaco-
therapy without analyzing a potential survival bias.2,9 Others
associate adverse outcome with surgical ligation without
analyzing confounding by indication, ie, major morbidities
that may serve as indication for surgical ligation and could
explain why infants with ligation are associated with worse
outcome.2,9 We attempted to correct both issues by restrict-
ing our analysis to infants comparable for ligation without
survival bias and by adding preligation confounders to a
model matching infants with and without surgical ligation.
Methods
This was a population-based, retrospective cohort study
including all live born infants between 220/7 and 276/7 weeks
of gestation in Switzerland from 2012 to 2017 who were
admitted to the neonatal ward. We excluded 27 infants
born and treated exclusively in 3 stepdown units, 87 infants
born with a major congenital malformation (defined as being
the primary cause of death or requiring surgery or having a
chromosomal anomaly), and 235 infants who died in the de-
livery room. The Swiss Neonatal Network & Follow-up
Group (SwissNeoNet) collects data prospectively and elec-
tronically for cohort studies.
Data collection and evaluation for this study were
approved by the Swiss Association of Research Ethics Com-
mittees (BASEC PB_2016-02299 and 2020-02443). Partici-
pating centers were obliged to inform parents about the
scientific use of anonymized data.
PDA was defined as symptomatic PDA, requiring phar-
macotherapy (indomethacin, ibuprofen, or paracetamol)
or surgical ligation. Most PDAs were confirmed by echocar-
diography by an in-house cardiologist. All but one smaller
center diagnosed PDA by performing routine echocardiog-
raphy. Gestational age was collected as the best-estimate
available based on prenatal ultrasound examination during
the first trimester of pregnancy. One day of oxygen (O2)
was defined as oxygen support ³12 hours above room air
concentration. Birth weight z scores (BWZ), IVH grades
3-4, NEC as of Bell stage ³2, late-onset neonatal sepsis
(LOS), and ROP stages 3-4 were defined as previously pub-
lished.13,14 Major morbidity was a composite outcome of
either IVH, NEC, LOS, O2 requirement ³28 days, or ROP.
Moderate-to-severe neurodevelopmental impairment
(NDI) at 2 years of age was a composite outcome including
mental, motor, and sensory function as previously
described.13,14
Patient population coverage was assessed by comparison
with the birth registry of the Swiss Federal Statistical Office
and yielded 91% of all live births between 22 and 27 weeks
of gestation. Data completeness and plausibility were
checked on electronic data entry. Missing data were
requested until completed. Each center is subject to data au-
dits every 3 years whereby SwissNeoNet verifies a random
sample of 10% of the submitted datasets with the original pa-
tient file. Accuracy is high (>95% of items). Data on
ROP were missing in 1.5% of surviving infants; the rate
of follow-up at 2 years of age was 84%. All other data were
complete.
We performed propensity score matching to compare in-
fants with surgical ligation (cases) with infants with pharma-
cotherapy (controls) and to compare infants born in centers
with greater than 10% surgical ligation (cases) with those
born in centers with lower than 10% (controls). Propensity
scores, ie, the probability of being in the case cohort, were
estimated from a logistic regression model that included
the covariates gestational age, BWZ, sex, being outborn,
and having either of the major morbidities IVH, NEC,
LOS, or ³28 days O2 before surgical ligation (preligation con-
founders). Each observation from the case cohort was
matched to one entry from the control having the closest pro-
pensity score.
Preligation confounders were added to the model as these
incidents could serve as an indication for ligation. They
include all IVH if ligation occurred after day of life (DOL)
3, as the risk of developing IVH is greatest during the first
72 hours of life and we did not have the information on exact
onset DOL for IVH.15 They further include all NEC and LOS
if ligation occurred after the onset day of NEC or LOS, and
for all occurrences of 28 days O2 treatment if ligation
occurred after DOL 28. Morbidities occurring after DOL 40
in nonligated infants were not included, as >95% of ligations
took place beforehand.
Statistical Analyses
We used the c2 test with the Yates correction for categorical
and the Mann–Whitney U test for metric variables. We per-
formed multivariable adjusted logistic regression to compare
outcomes between infants with and without surgical ligation
and between infants born in centers with lower or higher than
10% surgical ligation. Adjustment was made for gestational
age, BWZ, male sex, and outborn births. Other than in the
propensity score modeling, preligation confounders were
not added to the regression models, as they would introduce
bias by unilaterally adjusting for morbidities of infants with
surgical ligation if only those incidences count that occur
before a ligation, or morbidities of infants without surgical
ligation, as they could be interpreted as potential indication
for ligation as well. All statistical analyses were performed
using R, Version 3.6.1 (R Foundation for Statistical
Computing).16
Results
A total of 1389 infants were admitted to the 9 Swiss perinatal
centers between 2012 and 2017; 722 (52%) received pharma-
cotherapy and 156 (11.2%) received surgical ligation for a
PDA (Table I). Of the 156 infants with surgical ligation, 15
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(9.6%) died (Table I). This contrasts with the 242 (19.6%)
infants who died among the 1233 infants without ligation.
During DOL 1-10, 5 (3.2%) of the infants with ligation
died, whereas 164 (13.3%) of the infants without ligation
died. A Kaplan–Meier survival plot that simultaneously
displays the cumulative proportion of infants with ligation
over time (Figure 1) reveals however, that the majority of
surgical ligations were performed during a time when fewer
infants died. Comparing infants with and without surgical
ligation within the entire cohort (Table I) would therefore
constitute a survival bias. Instead, we chose DOL 10 as
threshold to include as many infants with ligation as
possible within a time period in which mortality was lower
than is usually observed during the first days after birth in
infants born extremely preterm. Table I reveals the cohort
restricted to infants who survived at least until DOL 10. All
further comparisons between infants with and without
surgical ligation are based on this cohort, within which
infants with ligation had lower median gestational age
(25.6 vs 26.6), lower median BWZ (0.2 vs 0.1), greater
proportions of LOS (32.5% vs 19.5%), IVH (15.9% vs
9.4%), NEC (11.9% vs 4.7%), need of O2 ³28 days (87.4%
vs 65.8%), ROP (13.5% vs 6.1%), and NDI (32.8% vs
19.7%). However, mortality was similar to that of infants
without ligation (6.6% vs 7.3%).
After we adjusted for case-mix in a logistic regression, in-
fants with ligation had a greater odds ratio for death or major
morbidity (OR 2.21, 95% CI 1.52-3.2), major morbidity (OR
2.33, 95% CI 1.61-3.36), and NDI (OR 1.86, 95% CI 1.21-
2.85) among the survivors until DOL 10 (Figure 2, A,
panel I). When we restricted the comparison to the 54.8%
infants at risk of adverse outcome due to PDA, ie, infants
with either pharmacotherapy or surgical ligation, the odds
for adverse outcome of infants with ligation were modestly
reduced (Figure 2, A, panel II).
To account for the possibility that infants received surgical
ligation because of their worse condition (confounding by
indication) vs developing the worse condition after or
because of the ligation, we performed propensity score
matching: one infant with ligation was matched with one
pharmacologically treated infant who had the closest propen-
sity score after including case-mix and preligation con-
founders. Infants with ligation had greater ORs for death
or major morbidity (OR 2.05, 95% CI 1.41-2.98), major
morbidity (OR 2.09, 95% CI 1.44-3.04), and NDI at 2 years
(OR 1.81, 95% CI 1.15-2.84) (Figure 2, A, panel III).
Using propensity score matching based on case-mix and
preligation confounders, wematched the 49 infants with liga-
tion during DOL 1-10 with those 49 pharmacologically
treated infants who had the nearest propensity score as a
sensitivity analysis. OR for mortality in infants with ligation
was 1.05 (95% CI 0.5-2.2).
Four of the Swiss centers performed surgical ligations on
>10% of their infants (range 13.9%-22.4%), 5 on <10%
(range 0%-9.1%). We split our collective into a group of in-
fants born in centers with a “high” proportion (n = 122/693;
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(n = 34/696; 4.9%) of surgical ligation (Table I). The 10%
threshold was chosen arbitrarily to form 2 groups of
similar size. Infants in the “high” group had a slightly
greater median gestational age (26.4 vs 26.3), a greater
proportion of NEC (7.9% vs 3.9%), and a tendency toward
lower proportion of IVH (12.7% vs 15.8%). In the “high”
group, surgical ligations were performed generally earlier
(median DOL = 12) than in the “low” group (median
DOL = 23). Table II lists the individual centers ordered by
the proportion of infants with ligation. None of the listed
center characteristics follow the exact same pattern.
Infants born in centers with high proportion of surgical li-
gations had greater odds for death or major morbidity (OR
1.45, 95% CI 1.15-1.83) and greater odds for major
morbidity (OR 1.42, 95% CI 1.13-1.78). Restricting the
cohort to infants at risk of adverse outcome due to PDA,
ie, infants who received either pharmacotherapy or surgical
ligation, revealed similar results (Figure 2, B, panel II).
We repeated the propensity score matching for the com-
parison between infants born in centers with high vs low pro-
portion of surgical ligation. Infants with PDA from the high
and low group were matched for case-mix and preligation
confounders. As result, infants in the high group had greater
odds for death or major morbidity (OR 1.49, 95% CI 1.11-2)
and major morbidity (OR 1.39, 95% CI 1.04-1.87) (Figure 2,
B, panel III).
Discussion
We present a population-based, geographically defined
cohort study, in which infants with surgically ligated PDA
were consistently associated with worse short- and long-
term outcome compared with infants receiving pharmaco-
logic treatment only, in crude, case-mix adjusted. and
propensity score analysis matched for case-mix and preliga-
tion confounders. For this analysis, the cohort was restricted
to infants who survived at least until DOL 10. DOL 10 was
chosen because the majority of surgical ligations took place
at the period after DOL 10 when mortality was more stable
(Figure 1). A comparison of the entire cohort as of DOL 1
would have introduced a selection bias benefitting infants
with surgical ligation, as more infants without ligation
would have been selected during the period in which
mortality is generally greatest among infants born
extremely preterm born whereas infants with ligation
would have predominantly been selected later. In a second
analysis, involving the entire cohort, infants born in
centers with greater than 10% surgical ligations had
greater odds for adverse short-term outcome than infants
born in centers in which fewer than 10% were ligated.
The proportion of infants treated for PDA in Switzerland
(54.8%) is somewhat greater than those of 5 other nations
recently reported by Isayama et al (range 34%-51%). Their
reported proportion of surgical ligation (range 6%-17%) is
comparable with ours (11.2%).4
Swiss adolescents who were surgically ligated during their
primary hospitalization reported lower health-related quality
of life than their peers.17 Other authors report adverse
outcome after 2 years associated with surgical ligation, partic-
ularly when selective criteria are missing.18,19 In an extensive
review, Weisz and McNamara list biological and clinical evi-
dence for a possible causal effect of surgical ligation on chronic
lung disease, ROP, and NDI.2 In a parallel systematic review,
they identify 40 observational studies that associated surgical
ligation with lower mortality but increased adverse outcome
after primary hospitalization and at 2 years of life. Nearly all
of these studies had at least a moderate risk of bias mainly
due to failure to adjust for survival bias and important post-
natal preligation confounders.9 Recent studies, however,
approach these issues. Mirea et al compared neonatal out-
comes according to PDA treatment assignment.20 After
adjustment for confounders, infants with ligation had lower
mortality but greater odds of bronchopulmonary dysplasia,
NEC, and ROP, compared with pharmacologically treated in-
fants. In a similar attempt to account for survival bias, they
restricted the comparison to infants surviving the first
3 days. Had we made the same restriction at 3 instead of
10 days, we would also report lower odds for mortality for in-
fants with rather than without surgical ligation (0.49, 95% CI
0.27-0.88). We, however, argue that in our case the compari-
son would still contain a selection bias as the bulk of infants
with ligation was recruited at a time when survival was stable
(Figure 1). The propensity score matching performed by
Mirea et al also revealed greater adverse outcome for infants
with surgical ligation. They, however, did not include
preligation confounders into their model.20 In a recent
multicenter study comparing pharmacologically treated vs
ligated infants, Weisz and McNamara found no increased
morbidities associated with surgical ligation using weighted
logistic regression including preligation confounding. To
account for survival bias, they restricted their cohorts at
DOL 7, 14, 19, and 28. Only at DOL 28 did they no longer
see a lower mortality associated with PDA ligations.5,21 In
contrast to our study, cases of PDA were included after
fulfilling a measure of severity (defined as ductal diameter
Figure 1. Kaplan–Meier survival plot and cumulative pro-
portion of PDA ligations. Note: none of the infants were
censored during the period displayed.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume-
4 Adams et al
³1.5 mm on at least 1 echocardiogram) and were compared
with surgical ligations that were performed in 3 centers
according to an agreed-on protocol after failure of
pharmacologic treatment. Their aim was to analyze outcome
difference between hemodynamically significant PDA with
pharmacotherapy vs surgical ligation, whereas ours was to
analyze the variation in outcome between centers in a
population-based setting when no universally agreed
treatment protocol exists.
We further analyzed this variation by comparing infants
treated in centers with high (>10%) and low (<10%) propor-
tion of ligation. It is noteworthy that infants of centers of the
high group showed greater odds for adverse outcome even af-
ter restricting the analysis to infants with PDA. The individ-
ual proportions of major morbidities of infants treated in the
9 perinatal centers reveals that those treated in centers of the
high group did not by chance follow the pattern of potentially
better vs worse outcome (Table II). The individual center’s
outcome may be influenced by a large selection of factors
not included in our analysis, such as antenatal/obstetrical
management, approaches to respiratory treatment, feeding
practices, etc. However, as our analysis focuses on surgical
Figure 2. OR for adverse outcome of A, infants with PDA ligation vs no PDA ligation and B, infants in unit with low vs high
proportion of PDA ligation. Major morbidity includes IVH grades 3-4, NEC (Bell stage 2 or greater), late-onset sepsis, O2 support
³28 days, and ROP stages 3-4. *Infants assessed at 2-year follow-up. N, number of matched cases.
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ligation and we compared infants from both groups after
propensity score matching for case-mix and preligation
confounding and restricted the cohort to infants receiving
treatment for PDA, the greater odds for adverse outcome
for infants of the high group may well be associated to
their center’s approach to surgical ligation.2,22-24 The
centers of the low group also did not have more delivery
room deaths. Thus, a survival bias by which infants at risk
for PDA died before being diagnosed can be ruled out
(Table II), nor is there an unambiguous geographic or
organizational pattern (type of center, size, or staffing) by
which the centers are grouped other than the greater
representation of local pediatric cardiac surgery
departments on the side of the high group. All centers
fulfill Swiss standard requirements for neonatal intensive
care.25 It is therefore not conceivable why infants born in
one-half of the Swiss centers should require 3 times as
many ligations than the other one-half. The observed
variation between these 2 center groups may therefore
fulfill Wennberg’s definition of being preference sensitive,
where treatment rates can vary extensively because of
differences in professional opinion, or even supply
sensitive, ie, where care comprises clinical activities for
which the frequency of use relates to the capacity of the
local healthcare system rather than evidence based need.26
As infants of our cohort receiving surgical ligation vs
pharmacotherapy have worse outcome, this variation is
unwarranted and may have a harmful effect.
Other studies have reported similar variation among peri-
natal centers.7,11,12 Despite large treatment differences, a
study from the Netherlands showed no difference in short-
term morbidity; however, perinatal center was a significant
predictor in a multivariable logistic regression.7 A study
from the United Kingdom reports significant variations in
the number of babies receiving pharmacotherapy in different
centers by neonatologists claiming to follow the same treat-
ment strategy.12 In the US, a survey reported a significantly
increased likelihood that a neonatologist would ligate a
PDA in infants who did not require mechanical ventilation
if the neonatologist believed that feedings had to be stopped
because of the PDA.11 In an analysis of treatment and
outcome variation among 6 countries including 139 centers,
both low and high PDA treatment rates (combining pharma-
cotherapy and ligation) were associated with death or severe
neurologic injury, whereas a moderate approach was associ-
ated with optimal outcome.4
In our study, we also observed that centers of the low
group performed surgical ligations later than those of the
high group. According to Benitz, delaying ligation may
have advantages, as it avoids surgery in many infants in
whom the ductus closes without treatment and reduces the
risk of postoperative hemodynamic compromise in those
who require surgery.22 Other studies reported no disadvan-
tage for a late vs early approach to surgery for short- or
long-term outcome.18,27
Our study has strengths and limitations. We evaluated
prospectively collected population-based data appraised for
accuracy and with a representative follow-up rate at 2 years
of age of 84%. We included case-mix and preligation con-
founding and examined 2 forms of survival bias. Limitations
concern the heterogeneity between centers in the diagnosis
and pharmacotherapy of infants with PDA. This may explain
some of the variation in the proportion of pharmacotherapy
per center (Table II), which, however, did not follow that of
surgical ligation. There is limited precision in determining
preligation confounding for IVH as we did not record an
onset DOL for IVH but instead assumed onset within the
first 72 hours for all IVH. This, however, favors the ligation
side of propensity score modeling, as each IVH counted as
potential indication for any ligation after DOL 3. Although
the treating center has been shown to be a determinant of
ligation frequency and outcome, we did not add it as co-
factor to either of the analyses, as this would have adjusted
the analysis for their effect on outcome. One of our aims,
however, was to reveal the effect that centers can have on
outcome. For the sake of completeness, we display the
outcome difference for infants with ligation additionally
adjusted for treating center in Figure 3, A (available at
www.jpeds.com). Restricting the comparison between
pharmacologically and surgically treated infants with PDA
to infants surviving at least until DOL 10 removes some
infants with PDA who died during this period who may
Table II. Grouping and characteristics of perinatal centers
Centers
Perinatal center group Center characteristics
Group Treated PDA Surgical PDA Delivery room deaths Major morbidities Local pediatric cardiac surgery
Center 1 Low 83 (59.3%) 0 (0%) 8 (5.4%) 42 (28.4%) No
Center 2 Low 32 (65.3%) 2 (4.1%) 2 (3.9%) 18 (35.3%) No
Center 3 Low 207 (70.2%) 15 (5.1%) 46 (13.5%) 128 (37.5%) Yes
Center 4 Low 50 (54.9%) 6 (6.6%) 25 (21.6%) 42 (36.2%) No
Center 5 Low 14 (11.6%) 11 (9.1%) 32 (20.9%) 29 (19%) No
Low total 386 (55.5%) 34 (4.9%) 113 (14%) 259 (32%)
Center 6 High 93 (56.4%) 23 (13.9%) 41 (19.9%) 81 (39.3%) Yes
Center 7 High 118 (52.2%) 35 (15.5%) 57 (20.1%) 89 (31.4%) Yes
Center 8 High 43 (32.6%) 26 (19.7%) 13 (9%) 42 (29%) No
Center 9 High 82 (48.2%) 38 (22.4%) 11 (6.1%) 87 (48.1%) Yes
High total 336 (48.5%) 122 (17.6%) 122 (15%) 299 (36.7%)
Total 722 (52%) 156 (11.2%) 235 (14.5%) 558 (34.4%)
Table is ordered by ascending proportion of surgical PDA.
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potentially have benefited from surgery. However, a
sensitivity analysis comparing the outcome of infants who
were ligated during the first 10 DOL to propensity score
matched pharmacologically treated infants reveals no lower
odds for mortality during this period. Nevertheless, our
result regarding the lack of association between surgical
ligation and mortality has to be treated with caution. For
the sake of completeness, we added an analysis that
compares infants with and without surgical ligation using
the cohort of all infants as of DOL 1 (Figure 3, B; available
at www.jpeds.com).
In conclusion, although the benefit of surgical ligations
should be considered for infants with severe forms of PDA,
our analysis places a clear burden on surgical ligation vs phar-
macotherapy in a population-based setting without
evidence-based guidelines. Infants born in centers with
more than 10% (median 17.6%) vs less than 10% surgical
ligation (median 4.9%), with ligation rates not following an
unambiguous geographical or organizational pattern, had
greater odds for adverse outcome. The combination of
greater odds for adverse outcome for children receiving sur-
gical ligation on the one hand and children born in centers
performing more surgical ligations on the other reveals an
unwarranted preference or supply-sensitive variation that
could be addressed to improve overall outcome. n
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Appendix
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Neonatology, Cantonal Hospital Aarau, Children’s Clinic,
Aarau, Switzerland
Andrea Capone Mori, MD, Daniela Kaeppeli, MD,
Department of Neuropaediatrics, Cantonal Hospital Aarau,
Children’s Clinic, Aarau, Switzerland
Sven M. Schulzke, Prof MD, Department of Neonatology
(S. M. Schulzke), University Children’s Hospital Basel
(UKBB), Basel, Switzerland
Marc Brotzmann, MD, Department of Neuropaediatrics
and Developmental Medicine, University Children’s Hospi-
tal Basel (UKBB), Basel, Switzerland
Gian Paolo Ramelli, Prof MD, Barbara Simonetti Goeggel,
Department of Pediatrics, San Giovanni Hospital, Bellin-
zona, Switzerland
Jane McDougall, Prof MD, Department of Neonatology,
University Hospital Berne, Berne, Switzerland
Tilman Humpl, Prof MD, Department of Pediatrics, Uni-
versity Hospital Berne, Berne, Switzerland
Maja Steinlin, Prof MD, Sebastian Grunt, PD, MD,
Department of Neuropaediatrics, University Hospital Berne,
Berne, Switzerland
Mathias Gebauer, MD, Department of Pediatrics, Chil-
dren’s Hospital Wildermeth, Biel, Switzerland
Ralph Hassink, MD, Development and Pediatric Neurore-
habilitation Center, Children’s Hospital Wildermeth, Biel,
Switzerland
Thomas Riedel, PD, MD, Department of Neonatology,
Children’s Hospital Chur, Chur, Switzerland
Elmar Keller, Prof MD, Christa Killer, MD, Department of
Neuropaediatrics Children’s Hospital Chur, Chur,
Switzerland
Gaelle Blanchard, MD, Department of Neuropediatrics,
Cantonal Hospital Fribourg, Fribourg, Switzerland
Riccardo E. Pfister, Prof MD, Neonatology Unit, Depart-
ment of child and adolescent, University Hospital (HUG),
Geneva, Switzerland
Petra S. Huppi, Prof MD, Cristina Borradori-Tolsa, MD,
Division of Development and Growth, Department of child
and adolescent, University Hospital (HUG), Geneva,
Switzerland
Jean-François Tolsa, Prof MD, Matthias Roth-Kleiner,
Prof MD, Department of Neonatology, University Hospital
(CHUV), Lausanne, Switzerland
Myriam Bickle-Graz, MD, Department of Child Devel-
opment, University Hospital (CHUV), Lausanne,
Switzerland
Martin Stocker, PD, MD, Neonatal and Paediatric Inten-
sive Care Unit, Children’s Hospital of Lucerne, Lucerne,
Switzerland
Thomas Schmitt-Mechelke, Prof MD, Florian Bauder,
MD, Department of Neuropaediatrics, Children’s Hospital
of Lucerne, Lucerne, Switzerland
Bernd Erkert, MD, Anita Mueller, MD, Department of Pe-
diatrics, Cantonal Hospital Muensterlingen, Muensterlingen,
Switzerland
Marc Ecoffey, MD, Department of Pediatrics, Cantonal
Hospital Neuchatel, Neuchatel, Switzerland
Andreas Malzacher, MD, Department of Neonatology,
Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Bjarte Rogdo, MD, Neonatal and Paediatric Intensive Care
Unit, Children’s Hospital St. Gallen, St Gallen, Switzerland
Anette Lang-Dullenkopf, MD, Department of Child
Development, Children’s Hospital St. Gallen, St. Gallen,
Switzerland
Lukas Hegi, MD, Department of Neonatology, Cantonal
Hospital Winterthur, Winterthur, Switzerland
Michael von Rhein, PD, MD, Social Pediatrics Center,
Cantonal Hospital Winterthur, Winterthur, Switzerland
Vera Bernet, Prof MD, Neonatal Unit, Hospital Zolliker-
berg, Zollikerberg, Switzerland
Maren Tomaske, Prof MD, Neonatal Unit, City Hospital
Triemli, Zurich, Switzerland
Dirk Bassler, Prof MD, MSc, Romaine Arlettaz, Prof MD,
Department of Neonatology, University and University Hos-
pital Zurich (USZ), Zurich, Switzerland
Cornelia Hagmann, Prof MD, Department of Neona-
tology, University Children’s Hospital Zurich, Zurich,
Switzerland
Bea Latal, Prof MD, Ruth Etter, MD, Child Development
Centre, University Children’s Hospital Zurich, Zurich,
Switzerland
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Figure 3. OR for adverse outcome ofA, infants with PDA ligation vs no PDA ligation as of DOL 10 andB, infants with PDA ligation
vs no PDA ligation as of DOL 1.Majormorbidity includes IVH grades 3-4, NEC (Bell stage 2 or greater), LOS, O2 support ³28 days,
and ROP stages 3-4. *Infants assessed at 2-year follow-up. §Including treating center as co-factor.
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